Tags

Type your tag names separated by a space and hit enter

Giardiasis: a pharmacotherapy review.
Expert Opin Pharmacother. 2007 Aug; 8(12):1885-902.EO

Abstract

Giardia lamblia, the cause of human giardiasis, is among the most common intestinal protozoa worldwide. Human infection may range from asymptomatic shedding of giardial cysts to symptomatic giardiasis, being responsible for abdominal cramps, nausea, acute or chronic diarrhoea, with malabsorption and failure of children to thrive. At present, treatment options include the nitroimidazoles derivatives; especially metronidazole, which has been the mainstay of treatment for decades and is still widely used. The increasing number of reports of refractory cases with this group of drugs and other antigiardial agents, has raised concern and led to a search for other compounds, some of which have arisen due to the introduction of drugs initially addressed to other diseases. The present article examines some of the most important points of antigiardial pharmacotherapy available at present and the future prospects of development of new agents.

Authors+Show Affiliations

Jefe del departamento de Microbiología y Parasitología, Hospital Pediatrico Universitario Pedro Borrás, Ciudad de La Habana, CP, Cuba. escobedo@infomed.sld.cuNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17696791

Citation

Escobedo, Angel A., and Sergio Cimerman. "Giardiasis: a Pharmacotherapy Review." Expert Opinion On Pharmacotherapy, vol. 8, no. 12, 2007, pp. 1885-902.
Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother. 2007;8(12):1885-902.
Escobedo, A. A., & Cimerman, S. (2007). Giardiasis: a pharmacotherapy review. Expert Opinion On Pharmacotherapy, 8(12), 1885-902.
Escobedo AA, Cimerman S. Giardiasis: a Pharmacotherapy Review. Expert Opin Pharmacother. 2007;8(12):1885-902. PubMed PMID: 17696791.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Giardiasis: a pharmacotherapy review. AU - Escobedo,Angel A, AU - Cimerman,Sergio, PY - 2007/8/19/pubmed PY - 2007/9/7/medline PY - 2007/8/19/entrez SP - 1885 EP - 902 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 8 IS - 12 N2 - Giardia lamblia, the cause of human giardiasis, is among the most common intestinal protozoa worldwide. Human infection may range from asymptomatic shedding of giardial cysts to symptomatic giardiasis, being responsible for abdominal cramps, nausea, acute or chronic diarrhoea, with malabsorption and failure of children to thrive. At present, treatment options include the nitroimidazoles derivatives; especially metronidazole, which has been the mainstay of treatment for decades and is still widely used. The increasing number of reports of refractory cases with this group of drugs and other antigiardial agents, has raised concern and led to a search for other compounds, some of which have arisen due to the introduction of drugs initially addressed to other diseases. The present article examines some of the most important points of antigiardial pharmacotherapy available at present and the future prospects of development of new agents. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/17696791/full_citation L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.8.12.1885 DB - PRIME DP - Unbound Medicine ER -